Meeting
2021 ASCO Annual Meeting
A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS).
Authors
Olubukola Ayodele
Princess Margaret Cancer Centre, Toronto, ON, Canada
Olubukola Ayodele , Ben X Wang , Thomas D Pfister , Esmail Mutahar Al-Ezzi , Hal Berman , Aaron Richard Hansen , Abha A. Gupta , Anna Spreafico , Limore Arones , Philippe L. Bedard , Lindsay Carlsson , Marcus O. Butler , Benjamin Haibe-Kains , Wei Xu , Lillian L. Siu , Albiruni Ryan Abdul Razak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03851614
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 11522)
DOI
10.1200/JCO.2021.39.15_suppl.11522
Abstract #
11522
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Deciphering the tumor microenvironment (TME) dynamics in advanced colorectal (CRC) and pancreatic cancers (PDAC) treated with durvalumab (D) with olaparib (O) or cediranib (C): Results from a phase 2 randomized trial.
First Author: Alberto Hernando-Calvo
Poster
2023 ASCO Annual Meeting
Immune correlates of outcome in patients with leiomyosarcoma (LMS) treated with durvalumab plus olaparib or cediranib: Transcriptome analysis from the DAPPER study.
First Author: Abdulazeez Salawu
Poster
2014 Gastrointestinal Cancers Symposium
Prognostic and predictive value of tumor-infiltrating immune cells in Japanese patients with stage II/III gastric cancer.
First Author: Sophie Earle
Poster
2013 ASCO Annual Meeting
Predictive value of tumor infiltrating lymphocytes (TIL) for response to breast cancer neoadjuvant chemotherapy (NCT).
First Author: Elena Garcia-Martinez